The privately-owned biotech company aims to provide cancer patients with efficient treatment without adverse effects by developing the next generation of chemotherapies. SEEKYO's smart drugs selectively target the microenvironment of solid tumors, safely transporting potent anticancer agents throughout the body while sparing healthy tissues. The company's chemotherapy is designed to provide harmless, efficient, and selective cell treatment by allowing the controlled release of the parent drug exclusively at the tumour site, based on its versatile enzyme-responsive self-immolative linker. SEEKYO's innovative approach to cancer treatment has the potential to revolutionize chemotherapy and improve the lives of cancer patients.